Patient copayment on Dupixent drops from 60% to 10%

By | translator Byun Kyung A

20.12.31 06:16:33

가나다라 0

300 mg of the atopic dermatitis treatment to be covered by special case benefit from Jan. 1, 2021

Patients to pay only 71,000 won per injection, costing approximately 2 million per year

Sales soar with reimbursement benefit, expected to accumulate 20 billion won in 2021

From the break of the new year, the copayment burden on the patients prescribed with an atopic dermatitis treatment Dupixent would be reduced significantly.

Sanofi Aventis Korea’s Dupixent would be applied with a special case reimbursement from Jan. 1, 2021 for the patients with severe case of atopic dermatitis. Accordingly, their copayment rate for administering 300 mg of Dupixent would be decreased from 60 percent to 10 percent.

The Health Insurance Policy Deliberation Committee (HIPDC) has made the decision at the 22nd meeting convened by the Ministry of Health and Welfare (MOHW) on Nov. 27 last year. A special case reimbursement benefit is provided to patients with rare or severe

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)